Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values

American Journal of Obstetrics and Gynecology

Volumn 174, Issue 1, 1996, Pages 107-114

  Bon, G G ^a   Kenemans, P ^a   Verstraeten, R ^a   Van Kamp, G J ^a   Hilgers, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

breast cancer; CA 125; CA 15.3; Ovarian cancer; reference values; tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; MONOCLONAL ANTIBODY; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; FEMALE; FEMALE GENITAL TRACT CANCER; GYNECOLOGIC CANCER; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOASSAY; MENOPAUSE; NORMAL HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REFERENCE VALUE;

EID: 0030030490     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(96)70381-2     Document Type: Article

References (25)

1. S Gendler C Lancaster J Taylor-Papadimitriou Molecular cloning and expression of human tumour-associated polymorphic epithelial mucin J Biol Chem 265 1990 15286 15293
2. AA Verstraeten GG Bon P Kenemans GJ van Kamp J. Hilgers Diagnostic and prognostic significance of the mucin serum tumor markers CA M26 and CA M29: theoretical considerations based on a review of the literature A Ballesta GC Torre E Bombardieri M Gion R Molina Updating on tumor markers in tissue and biological fluids: basic aspects and clinical applications 1993 Edizioni Minerva Medica Torino, Italy 575 587
3. P Kenemans RC Bast CA Yedema MR Price J. Hilgers Polymorphic epithelial mucin as serum tumor marker J Hilgers A Zotter Polymorphic epithelial mucin and CA-125 bearing glycoprotein as tumor-associated antigens 1988 Munksgaard Copenhagen 11/12/119 11/12/144
4. GG Bon P Kenemans GJ van Kamp CA Yedema J. Hilgers Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients Nucl Med Allied Sci 34 suppl 1990 151 162
5. DF Hayes VR Zurawski Jr DW. Kufe Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer J Clin Oncol 4 1986 1542 1550
6. C Yedema P Kenemans T Wobbes Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix Int J Cancer 47 1991 170 179
7. C Stähli M Caravatti M Aeschbacher C Kocyba B Takacs H Carmann Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes Cancer Res 48 1988 6799 6802
8. J Brown P Linsley D. Horn Breast carcinoma-associated mucins as tumor markers: development and evaluation of monoclonal antibody - based immunoassays R Herberman D Mercer Immunodiagnosis of cancer 1989 Marcel Dekker New York 69 82
9. HE. Solberg Establishment and use of reference values NW Tietz Fundamentals of clinical chemistry 1987 WB Saunders Philadelphia 197 212
10. JT Servaas PWJ van Dongen P. Kenemans Early detection of ovarian neoplasia in asymptomatic women by ultrasonography and serum CA125 and CA19.9 levels [Abstract] Proceedings of the World Congress of Gynecology and Obstetrics, Rio de Janeiro, Brazil, October 23-28, 1988 1988 World Congress of Gynecology and Obstetrics Rio de Janeiro 25
11. P Kenemans GJ van Kamp P Oehr RA. Verstraeten Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum Clin Chem 39 1993 2509 2513
12. E Bombardieri M Gion R Mione R Dittadi G Bruscagnin R. Buraggi A mucinous-like carcinoma associated antigen in the tissue and blood of patients with primary breast cancer Cancer 63 1989 490 495
13. C Bieglmayer T Szepesi W Neunteufel C. Nowontny MCA, a monoclonal-antibody - defined breast-tumor - associated antigen and its relation to CA 15.3 Tumor Biol 10 1989 232 242
14. International Federation of Clinical Chemistry The theory of reference values V. J Clin Chem Clin Biochem 25 1987 645 656
15. B Dawson-Saunders RG. Trapp Basic and clinical biostatistics 1990 Prentice-Hall International Englewood Cliffs, New Jersey
16. C. Wagener Sensitivity, specificity and predictive value of tumour marker determination J Clin Chem Biochem 22 1984 969 979
17. G Soletormos V Schioler D Nielsen Skovsgaard Torben P. Dombernowsky Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation Clin Chem 39 1993 2077 2083
18. S Grover MA Quin P Weideman H. Koh Factors influencing serum CA 125 levels in normal women Obstet Gynecol 79 1992 511 514
19. S Grover H Koh P Weideman MA. Quinn The effect of the menstrual cycle on serum CA 125 levels: a population study AM J OBSTET GYNECOL 167 1992 1379 1381
20. P Kenemans CA Yedema GG Bon S. von Mensdorff-Pouilly CA 125 in gynecological pathology - a review Eur J Obstet Gynecol Reprod Biol 49 1993 115 124
21. N Fujino Y Haga K Sakamoto Clinical evaluation of an immunoradiometric assay for CA 15-3 antigen associated with human carcinomas: comparison with carcinoembryonic antigen Jpn J Clin Oncol 16-4 1986 335 346
22. M Gion R Mione R Dittadi S Fasan A Pallini G. Bruscagnin Evaluation of CA 15.3 serum levels in breast cancer patients J Nucl Med Allied Sci 30 1986 29 36
23. P Schmidt-Rhode K-D Schulz G Sturm A Raab-Frick H. Prinz CA 15.3 in breast cancer: first experience with a new monoclonal test system Med Sci Res 15 1987 765 766
24. R Colomer A Ruibal D Genolla Rubio JM Del Campo R Bodi L. Salvador Circulating CA 15.3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases Breast Cancer Res Treat 13 1989 123 133
25. GJ van Kamp KA Yedema A Kok R Poort J Hilgers P. Kenemans Evaluation of an EIA kit for carcinoma-associated mucin antigens CA M26 and CA M29 Tumor Marker Oncol 4 1989 363 372